SAN FRANCISCO--(BUSINESS WIRE)--Counsyl, a health technology company that offers DNA screening for diseases that can impact men, women and their children, today announced that Dan Puckett has joined the company as chief financial officer. With more than 25 years of finance and operations experience, Puckett will be responsible for financial management and strategy at Counsyl.
“Dan has a unique blend of experience. Not only does he have a proven track record of developing and growing businesses from a financial perspective, but he is also well-versed in the genetics and healthcare industries,” said Ramji Srinivasan, cofounder and chief executive officer of Counsyl. “Counsyl is at the forefront of bringing breakthrough clinical services to physicians and patients, and Dan’s expertise will help to propel us to the next level.”
Prior to Counsyl, Puckett served as chief financial officer for Ariosa Diagnostics (acquired by Roche earlier this year), where he was responsible for leading the finance and human resources functions. Previously, Puckett also served as executive director of operations at Cerexa, a Forest Laboratories subsidiary. In this role, he was part of the leadership team responsible for obtaining FDA approval for the drug Teflaro. Before Cerexa, Puckett held senior finance and operations positions at Affymetrix, AOL, Viad, and BHP Billiton.
“Counsyl is making tremendous strides in furthering the affordability and accessibility of genetic screening, so that everyone can benefit from understanding what specific DNA mutations they carry and how to act on that information,” said Dan Puckett. “I’m excited to be joining Counsyl at such a pivotal time in the industry and look forward to working closely with the team to help deliver on Counsyl’s vision of broadening access to genetic information.”
Puckett received an M.B.A. from the University of San Francisco and a B.A. degree in accounting from Washington State University.
Counsyl offers DNA screenings for key times in people’s lives - for those starting a family, and for those at risk for inherited cancer. For more information on Counsyl, please visit www.counsyl.com.
Counsyl is a health technology company that offers DNA screening for diseases that can impact men, women and their children. The Counsyl philosophy is simple: screen for diseases where advanced knowledge makes a difference in health outcomes, whether it’s changing a behavior, pursuing preventative measures, or simply preparing for what lies ahead.
The Counsyl team includes an accomplished group of problem-solvers — top engineers, scientists, and designers — who are taking the lead on building the modern clinical laboratory. Scientific rigor, custom robotics, and software are at the heart of every Counsyl product, resulting in better, faster and more affordable screens that are broadly accessible. Beyond the laboratory, Counsyl offers doctors and patients a technology platform for results delivery in real time, with on-demand access to board-certified genetic counselors.
Counsyl has screened more than 400,000 patients and served more than 6,000 health care professionals in its CLIA-certified, CAP-accredited and NYS CLEP-permitted clinical laboratory. The company has raised a total of $102 million and is privately backed by RSTP, Goldman Sachs Asset Management, Founders Fund, Felicis Ventures, David Drummond, and other high profile investors.